square foot expansion to support the process development
and kilo lab scale, and become a general GMP CMO.
In 2004 they were acquired by Sigma-Aldrich. According
to Matt Hanson, the Global Market Segment Manager, “SAFC
recognized it as a real opportunity to get into the highly
active business,” and has continued to see the value and
growth potential in the high-potency marketplace. Just two
years after acquisition, the Madison facility underwent a
38,000 square foot expansion, effectively doubling the site in
size and increasing the cGMP manufacturing capabilities.
The nature of the Madison location meant that the 2006
expansion would be the limit of their ability to expand further
on that site, so in 2008 the Verona land was acquired just a few
miles out of town and construction there began in 2010. The
scenic site just outside of Madison was completed this fall, with
lab validations still in progress at the time of our visit.
Although the sites are technically located in different cities, they are both run by the same management team with
site-specific individuals, as a uniform operational entity.
The two sites together can handle upwards of 50 projects
throughout a year period, and SAFC has produced well over
20 commercial APIs out of the Madison facility.
SAFC, a global supplier of a a wide range of services to the biopharm and pharmaceutical industry, has recently expanded their Madison, Wisconsin facili- ties to neighboring Verona to rev up their high-potency API manufacturing capabilities. The original Madison
facility works in concert with the new, large scale manufacturing facility in Verona to provide customers support from
the pre-clinical through commercial stages of development
and manufacturing. With more than 20 years of experience
in highly complex chemistry, the Madison/Verona facilities
are SAFC’s primary center for high-potency development.
The original facility, located in the heart of Madison’s
University Research Park, actually began it’s time in the
high-potency arena as Tetrionics Inc., established in 1989,
by Herb Paaren and Peter Johnson, with the help of UW-Madison Professor Hector DeLuca. The company can trace
its scientific roots back to the early vitamin D work of
renowned UW-Madison Professor Harry Steenbock. The
company achieved great success upon the development of
its vitamin D analog, later commercialized in Zemplar in
the late nineties. That success solidified their place in the
niche market and enabled the company to complete a 25,000
SAFC's Madison, WI operations expand to become a center for high-
High Potency, High
■ By Nikita Ernst, Associate Editor